1st Quarter - Report

WEST FRONT STRATEGIES LLC for FRESENIUS KABI USA LLC

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues related to patent policy and reform, including terminal disclaimers; FDA/PTO Coordination, including Interagency Patent Coordination and Improvement Act of 2023 (S.79); Prescription Pricing for the People Act of 2023 (S.113); Preserve Access to Affordable Generics and Biosimilars Act (S.142); Affordable Prescriptions for Patients Act of 2023 (S.150).

LobbyistCovered position, as disclosed
CHRISTOPHER BUKI —
ASHLEY DAVIS —
CRAIG KALKUT —
MALLOY MCDANIEL —
KRISTI REMINGTON —
SHIMON STEIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 113 (118th), S. 79 (118th), S. 142 (118th), S. 150 (118th)

Medicare/Medicaid MMM

Formulary placement of generics and biosimilar biological products in Part D; issues related to access to biosimilar biological products in Medicare Part B; issues related to rebate walls.

LobbyistCovered position, as disclosed
CHRISTOPHER BUKI —
ASHLEY DAVIS —
CRAIG KALKUT —
MALLOY MCDANIEL —
KRISTI REMINGTON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

Issues related to drug pricing; issues related to Biosimilars; issues related to competition.

LobbyistCovered position, as disclosed
CHRISTOPHER BUKI —
ASHLEY DAVIS —
CRAIG KALKUT —
MALLOY MCDANIEL —
KRISTI REMINGTON —
SHIMON STEIN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.